bexmarilimab
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 7, 2021 (NCT05104905)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Kinesin-like protein 1ANTAGONIST
KIF11 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594544 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05428969 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2022 | Faron Pharmaceuticals Ltd, University of Helsinki |
| NCT05104905 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2021 | Faron Pharmaceuticals Ltd, University of Turku |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Faron Pharmaceuticals Ltd | For profit | 2 | 2 | 1 | 2021 |
| University of Helsinki | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Turku | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1